News

As per the terms of the agreement, Biovista will collaborate with Pfizer’s Indications Discovery Unit to identify up to three novel indications for each of the Pfizer candidates.

The collaboration is designed to create new opportunities to further improve the efficacy of several of Merial’s new vaccine development targets. In Cell Art claims that the ICA614

Opexa’s operating loss was $1.29m, compared to $1.21m for the comparable period in 2009. For the nine months ended 30 September 2010, the company has posted a net

The grant was awarded under the Foundation’s Therapeutics Development Initiative aimed at supporting preclinical development of Parkinson’s disease therapies that have the potential for fundamentally altering disease course

PharmFilm is designed to benefit patients by improving the convenience, efficacy, and compliance of new and currently marketed drugs, MonoSol Rx said. MonoSol Rx president and CEO Mark

Snowdon is a biopharmaceutical company that specialises in the discovery and development of novel small-molecule therapeutics for the treatment of pain, infectious diseases and nervous system disorders Snowdon

EUSA Pharma submitted its Erwinase BLA on a rolling basis, following receipt of Fast Track designation from the FDA. EUSA Pharma’s completed BLA submission requests Priority Review status,

Unigene Laboratories designs, manufactures and develops peptide-based therapeutics. The company is building a portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence platform. Unigene

Biosof claims that PubSeq is a novel scientific knowledge management system capable of mining the scientific literature for meaningful, accurate and relevant data. The award was made through